Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: A randomized trial

Journal of Infectious Diseases

Volumn 213, Issue 7, 2016, Pages 1134-1142

  Yeka, Adoke ^a,c   Kigozi, Ruth ^c   Conrad, Melissa D ^h   Lugemwa, Myers ^d   Okui, Peter ^d   Katureebe, Charles ^e   Belay, Kassahun ^f   Kapella, Bryan K ^g   Chang, Michelle A ^g   Kamya, Moses R ^b,c   Staedke, Sarah G ^c,i   Dorsey, Grant ^h   Rosenthal, Philip J ^h  

^a Makerere College of Health Sciences   (Uganda)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^d MINISTRY OF HEALTH   (Uganda)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f US Agency for International Development   (Uganda)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Amodiaquine artesunate; Artemether lumefantrine; Drug resistance; Malaria; Uganda

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; HEMOGLOBIN; AMODIAQUINE; AMODIAQUINE, ARTESUNATE DRUG COMBINATION; ARTEMISININ DERIVATIVE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ABDOMINAL PAIN; ANOREXIA; ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CHILD; COMMON COLD; CONTROLLED STUDY; CONVALESCENCE; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GENE; GENETIC POLYMORPHISM; HEADACHE; HEALTH CENTER; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTICENTER STUDY; PALLOR; PFCRT GENE; PFMDR1 GENE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TREATMENT OUTCOME; TREATMENT RESPONSE; UGANDA; VOMITING; WILD TYPE; DRUG COMBINATION; MALARIA, FALCIPARUM;

AMODIAQUINE; ARTEMISININS; CHILD, PRESCHOOL; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; UGANDA;

EID: 84962594969     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv551     Document Type: Article

References (45)

1. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM. Malaria. Lancet 2014; 383:723-35.
2. World Health Organization. World malaria report 2014. Geneva: World Health Organization, 2104.
3. Four Artemisinin-Based Combinations Study G. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011; 8:e1001119.
4. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014; 371:411-23.
5. Conrad MD, Bigira V, Kapisi J, et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One 2014; 9:e105690.
6. Taylor SM, Parobek CM, DeConti DK, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 2015; 211:680-8.
7. Cooper RA, Conrad MD, Watson QD, et al. Lack of artemisinin resistance in Plasmodium falciparum in Uganda based on parasitological and molecular assays. Antimicrob Agents Chemother 2015; 59:5061-4.
8. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007; 77(6 suppl):181-92.
9. Rosenthal PJ. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol 2013; 89:1025-38.
10. Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine+ sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365:1474-80.
11. Martensson A, Stromberg J, Sisowath C, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005; 41:1079-86.
12. Bukirwa H, Yeka A, Kamya MR, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials 2006; 1:e7.
13. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210-9.
14. Kabanywanyi AM, Mwita A, Sumari D, Mandike R, Mugittu K, Abdulla S. Efficacy and safety of artemisinin-based antimalarial in the treatment of uncomplicated malaria in children in southern Tanzania. Malar J 2007; 6:146.
15. Adjei GO, Kurtzhals JA, Rodrigues OP, et al. Amodiaquine-artesunate vs artemether- lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J 2008; 7:127.
16. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM. High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health 2008; 13:635-43.
17. Faye B, Offianan AT, Ndiaye JL, et al. Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Int Health 2010; 15:608-13.
18. Michael OS, Gbotosho GO, Folarin OA, et al. Early variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance. Malar J 2010; 9:335.
19. President's Malaria Initiative. Uganda Malaria Operational Plan FY 2014. 2014.
20. Uganda Bureau of Statistics. Uganda Malaria Indicator Survey 2014-15. 2015.
21. Humphreys GS, Merinopoulos I, Ahmed J, et al. Amodiaquine and artemetherlumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother 2007; 51:991-7.
22. Nsobya SL, Dokomajilar C, Joloba M, Dorsey G, Rosenthal PJ. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate- amodiaquine in Uganda. Antimicrob Agents Chemother 2007; 51:3023-5.
23. Sisowath C, Stromberg J, Martensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 2005; 191:1014-7.
24. Zongo I, Dorsey G, Rouamba N, et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007; 369:491-8.
25. Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis 2011; 204:1120-4.
26. Conrad MD, LeClair N, Arinaitwe E, et al. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis 2014; 210:344-53.
27. Tumwebaze P, Conrad MD, Walakira A, et al. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children. Antimicrob Agents Chemother 2015; 59:3018-30.
28. Mbogo GW, Nankoberanyi S, Tukwasibwe S, et al. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am J Trop Med Hyg 2014; 91:54-61.
29. Kilama M, Smith DL, Hutchinson R, et al. Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. Malar J 2014; 13:111.
30. Greenhouse B, Myrick A, Dokomajilar C, et al. Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. Am J Trop Med Hyg 2006; 75:836-42.
31. Leclair NP, Conrad MD, Baliraine FN, Nsanzabana C, Nsobya SL, Rosenthal PJ. Optimization of a ligase detection reaction fluorescent microsphere assay for the characterization of resistance-mediating polymorphisms in African samples of Plasmodium falciparum. J Clin Microbiol 2013; 51:2564-70.
32. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization, 2009.
33. Francis D, Nsobya SL, Talisuna A, et al. Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis 2006; 193:978-86.
34. Ndiaye JL, Randrianarivelojosia M, Sagara I, et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ-a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J 2009; 8:125.
35. Owusu-Agyei S, Asante KP, Owusu R, et al. An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. PLoS One 2008; 3:e2530.
36. Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000; 403:906-9.
37. Sidhu AB, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol 2005; 5:913-26.
38. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisininresistant Plasmodium falciparum malaria. Nature 2014; 505:50-5.
39. Borrmann S, Straimer J, Mwai L, et al. Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. Sci Rep 2013; 3:3318.
40. Henriques G, Hallett RL, Beshir KB, et al. Directional selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J Infect Dis 2014; 210:2001-8.
41. Sutherland CJ, Babiker H, Mackinnon MJ, Ranford-Cartwright L, El Sayed BB. Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric malaria cases? Parasitology 2011; 138:1459-68.
42. Kamya MR, Yeka A, Bukirwa H, et al. Artemether-lumefantrine versus dihydroartemisinin- piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials 2007; 2:e20.
43. Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin- piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008; 3:e2390.
44. Nankabirwa JI, Wandera B, Amuge P, et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis 2014; 58:1404-12.
45. Bigira V, Kapisi J, Clark TD, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 2014; 11:e1001689.